ClinicalTrials.gg
CompletedNCT00445276Updated Mar 4, 2010

Symptomatic Efficacy of Diacerein in Knee Osteoarthritis

A Phase 4 interventional study of Diacerein in Knee Osteoarthritis, sponsored by Laboratoires NEGMA. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-03-04.

Sponsored by Laboratoires NEGMA (part of Wockhardt) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 124 studies in Osteoarthritis, Knee with a site in France — 23 open to participants now, 33 under way, 1 of them phase 3. Osteoarthritis, Knee · France.

Enrollment
5th of 86
500 · median 106
Started
2005
with 5 others
Phase 4
6 of 124
1 open now
Registered
8th of 124
by date

Among the 124 studies in Osteoarthritis, Knee with a site in France, this one is the 5th largest by enrollment of the 86 interventional ones that give a count, is one of 6 that started in 2005, is one of 6 in phase 4, and was the 8th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

23 of the 124 studies in Osteoarthritis, Knee with a site in France are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Osteoarthritis, Knee with a site in France, or all of them as a file.
02

Study summary

Pain is the main symptom of osteoarthritis that motivates medical visits. Diacerhein has already demonstrated its efficacy in knee and/or hip osteoarthritis. This study aims at confirming the efficacy of diacerhein in symptomatic knee osteoarthritis using known and validated criteria and according to the recommendations and guidelines for this kind of study.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Osteoarthritis
  • Knee
  • Diacerein
  • Painful osteoarthritis
  • Clinical trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Painful primary osteoarthritis (VAS ≥ 40 mm)
  • Radiologically proven (Kellgren \& Lawrence grade I to III)
  • Requiring the prescription of a symptomatic treatment of pain

Exclusion criteria

Exclusion Criteria:

  • Severe associated diseases
  • Wash-out: AINS, Coxibs, Paracetamol, anti-osteoarthritic treatments, hyaluronic acid, knee tidal lavage
  • Other osteoarticular disease
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
500 participants

Interventions

06

What researchers measure

Primary outcomes

  1. VAS on pain movement, WOMAC A 1.1 section

Secondary outcomes

  1. WOMAC : total, pain, physical function

  2. Paracetamol consumption

  3. Global assessment of the patient

  4. Responder patients with OMERACT-OARSI criteria

  5. Tolerance

07

Study locations

1 site
  • Chu Trousseau
    Tours, 37044, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005, a primary completion of Sep 2006 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2007
First posted
Mar 8, 2007
Start
Nov 2005
Primary completionActual
Sep 2006
CompletionActual
Sep 2006
Last update
Mar 4, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00445276
Lead sponsor
Laboratoires NEGMA
First posted
Mar 8, 2007
Start date
Nov 2005
Primary completion
Sep 2006
Completion
Sep 2006
Last update
Mar 4, 2010

Study contacts

Jean - Pierre Valat
principal investigator · Unafilliated

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diacerein

Start the discussion